Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters highlighting compelling data and clinical progress for its lead radiopharmaceutical candidate, iopofosine I 131 in Waldenström macroglobulinemia (WM), will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 12 – 15 in New Orleans, Louisiana.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.